Corporate Reputation of Pharma Companies, 2016-2017: Perspective of 100 German Patient Groups - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 100 German Patient Groups - 4th Edition" report has been added to Research and Markets' offering.

These results are derived from a global review of pharma's corporate reputation (conducted November 2016 to early-February 2017).

The results form the opinions of 100 German patient groups: 22 specialised in cancer; 11 in mental health; 8 in rare diseases; 6 in multiple sclerosis; and other specialties.

21 pharma companies are included in this 2016 German analysis:

• Amgen (new to the German analysis)
• AstraZeneca
• Bayer
• Biogen (new)
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Eli Lilly (Lilly)
• Grnenthal
• GSK
• Janssen
• Merck & Co
• Merck KGaA
• Novartis
• Novo Nordisk (new)
• Pfizer
• Roche
• Sandoz
• Sanofi
• Stada Arzneimittel
• Takeda (new)
• Teva (new)

The 21 companies were chosen because a minimum of 19 German patient groups declared familiarity with each one.

In response to a survey of pharmaceutical companies, only Bayer Vital GmbH provided information on its patient centricity and relations with patient-advocacy groups during 2016-2017 in Germany.

THE QUESTIONNAIRE

Industry-wide questions:

• How the pharma industry's corporate reputation compares with that of other healthcare industries.
• How the pharma industry's corporate reputation has changed over the past five years.
• How good or bad the pharma industry is at various activities of relevance to patients and patient groups.

7 indicators show the corporate reputation of individual pharma companies:

1. Patient centricity.
2. Information for patients.
3. Patient safety.
4. Usefulness of products.
5. Transparency.
6. Integrity.
7. Patient-group relationships (new for 2016).

INDUSTRY-WIDE FINDINGS

• In 2016, only 19% of German patient groups thought that the pharma industry had an Excellent or Good corporate reputation, compared with 38% of patient groups worldwide.
• The 2016 results were the most negative ratings from German patient groups since 2012.
• German patient groups ranked the pharma industry 7th in 2016 among eight healthcare-industry sectors for having an Excellent or Good corporate reputation. By contrast, patient groups from all geographic areas ranked pharma 5th in 2016.
• German patient groups were, however, more positive about the industry's levels of innovation, and about its ability to create high-quality products [see chart, below]. 54% and 55% of the 100 German patient groups described pharma as Excellent or Good at these two activities in 2016, respectively.
• However, the pharmaceutical industry was marked down by German patient groups for its other activitiesmost notably, fair pricing. Just 3% of the 100 German patient groups called pharma Excellent or Good at this activity in 2016. Only patient groups from Ireland and the Netherlands graded pharma lower for this activity (with a score of zero).

PHARMA COMPANIES and GERMAN PATIENT GROUPS

• The company with which German patient groups were most familiar in 2016 was Roche (73 of the 100 respondent German patient groups were familiar with the company), followed by Novartis (71), and Pfizer (69).

INDIVIDUAL COMPANY FINDINGS GERMANY

• Amgen (new to the German analysis) ranked overall 1st in 2016 for corporate reputation among the 23 respondent German patient groups familiar with the company.
• Amgen also ranked 1st in 2016 for four of the seven indicators of corporate reputation. The exceptions were patient safety, provision of high-quality products, and integrity.
• Novo Nordisk (also new to the German analysis) was ranked 1st in 2016 for these latter three indicators by the 19 respondent German patient groups familiar with the company.

HIGHS and LOWS GERMANY

• If the German corporate-reputation results for 2016 (21 pharma companies analysed) are compared with those of 2015 (16 pharma companies analysed) using a standardised index the Patient Corporate Reputation Index (PCRI)findings show the biggest jumps up the German rankings were for:
• Merck & Co, which ranked 11th overall out of 21 companies in 2016 (compared with 15th out of 16 companies in 2015).
• AstraZeneca, which ranked 9th overall out of 21 companies in 2016 (compared with 12th out of 16 companies in 2015).
• Bristol-Myers Squibb, which ranked 7th out of 21 companies overall in 2016 (compared with 10th out of 16 companies in 2015).

For more information about this report visit https://www.researchandmarkets.com/research/tdf8tt/the_corporate